Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions. | Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. | AbbVie AbbVie is a pharmaceutical company engaged in the research, development, manufacturing, commercialization, and sale of medicines and therapies. | Nipro Nipro Corporation (ニプロ株式会社) is a company that has expertise in medical devices, pharmaceuticals, pharma packaging, and regenerative medicine business. | Shionogi Shionogi (塩野義製薬株式会社) is a pharmaceutical company developing treatments for infectious, pain, and chronic liver diseases. | Hetero Hetero is a generic pharmaceutical company engaged in the development, manufacturing, and marketing of chemical and biologic drugs. | ||
Founding Date | Founding Date 1923 | Founding Date 1849 | Founding Date 2013 | Founding Date 1863 | Founding Date 1954 | Founding Date 1878 | Founding Date 1993 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Private |
Tags | |||||||
Locations | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Bentley, AU Footscray, AU Mulgrave, AU Sydney, AU see more | Locations North Chicago, US HQ Alger, DZ Buenos Aires, AR Mascot, AU Wien, AT Wavre, BE Sarajevo, BA see more | Locations Osaka, JP HQ Beijing, CN Hong Kong, HK Amagasaki, JP Amagasaki, JP Kanegasaki, JP Misato, JP see more | Locations Hyderabad, IN HQ Norwest, AU Sao Paulo, BR Beijing, CN Nanjing Shi, CN Nanjing Shi, CN Bogotá, CO see more | ||
Employees | Employees 14,754 | Employees 83,0005% increase | Employees 50,000 | Employees 94,2454% decrease | Employees 38,117 | Employees 4,959 | Employees 6,1712% increase |
Valuation ($) | Valuation ($) 20.8 b | Valuation ($) 163.9 b | Valuation ($) 335 b | Valuation ($) 27.1 b | Valuation ($) 1.5 b | Valuation ($) 12.3 b | Valuation ($) N/A |
Financial | |||||||
Revenue (est.) | Revenue (est.) ¥1.6t (FY, 2024) | Revenue (est.) $58.5b (FY, 2023) | Revenue (est.) $54.3b (FY, 2023) | Revenue (est.) €47.6b (FY, 2023) | Revenue (est.) ¥586.8b (FY, 2024) | Revenue (est.) ¥410.1b (FY, 2024) | Revenue (est.) N/A |
Cost of goods | Cost of goods ¥134.6b (FY, 2024) | Cost of goods $25b (FY, 2023) | Cost of goods $20.4b (FY, 2023) | Cost of goods €7b (FY, 2023) | Cost of goods ¥356.6b (FY, 2024) | Cost of goods ¥39.3b (FY, 2024) | Cost of goods N/A |
Gross profit | Gross profit ¥1.5t (FY, 2024) | Gross profit $33.5b (FY, 2023) | Gross profit $33.9b (FY, 2023) | Gross profit €42.1b (FY, 2023) | Gross profit ¥230.2b (FY, 2024) | Gross profit ¥395.8b (FY, 2024) | Gross profit N/A |
Net income | Net income ¥17b (FY, 2024) | Net income $2.2b (FY, 2023) | Net income $4.9b (FY, 2023) | Net income (€2.9b) (FY, 2023) | Net income ¥12.2b (FY, 2024) | Net income ¥160.6b (FY, 2024) | Net income N/A |
Operating ⚠ | |||||||
Countries | Countries N/A | Countries 125 (FY, 2021) | Countries 70 (FY, 2022) | Countries 83 (FY, 2021) | Countries N/A | Countries N/A | Countries 126 (Jan, 2021) |
Manufacturing Facilities | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 19 (FY, 2022) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 4 (FY, 2018) | Manufacturing Facilities 36 (Jan, 2021) |
Funding | |||||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 3.5b | Total funding raised N/A | Total funding raised $ 4.7m | Total funding raised N/A |